A Phase II Study With Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2019
Price : $35 *
At a glance
- Drugs Orteronel (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- 18 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated
- 08 Mar 2018 Planned End Date changed from 1 Dec 2018 to 1 Feb 2020.